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Abstract
This part of the EFISG guidelines focuses on non-neutropenic adult patients. Only a few of the numerous recommendations can be sum-
marized in the abstract. Prophylactic usage of ﬂuconazole is supported in patients with recent abdominal surgery and recurrent gastroin-
testinal perforations or anastomotic leakages. Candida isolation from respiratory secretions alone should never prompt treatment. For
the targeted initial treatment of candidaemia, echinocandins are strongly recommended while liposomal amphotericin B and voriconaz-
ole are supported with moderate, and ﬂuconazole with marginal strength. Treatment duration for candidaemia should be a minimum of
14 days after the end of candidaemia, which can be determined by one blood culture per day until negativity. Switching to oral treat-
ment after 10 days of intravenous therapy has been safe in stable patients with susceptible Candida species. In candidaemia, removal of
indwelling catheters is strongly recommended. If catheters cannot be removed, lipid-based amphotericin B or echinocandins should be
preferred over azoles. Transoesophageal echocardiography and fundoscopy should be performed to detect organ involvement. Native
valve endocarditis requires surgery within a week, while in prosthetic valve endocarditis, earlier surgery may be beneﬁcial. The antifun-
gal regimen of choice is liposomal amphotericin B +/) ﬂucytosine. In ocular candidiasis, liposomal amphotericin B +/) ﬂucytosine is rec-
ommended when the susceptibility of the isolate is unknown, and in susceptible isolates, ﬂuconazole and voriconazole are alternatives.
Amphotericin B deoxycholate is not recommended for any indication due to severe side effects.
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Introduction
Invasive candidiasis remains a challenging complication, which
frequently occurs in patients with one or more underlying
diseases or surgical interventions. In recent point prevalence
studies, a candidaemia incidence of 6.9 per 1000 ICU
patients was reported, and 7.5% of ICU patients received
antifungal therapy [1,2]. Candidaemia increases mortality
rates in the range of 20–49% [3,4], but still there are many
open management questions.
The unmet medical needs surrounding candidaemia and
invasive candidiasis are deﬁned in general from diagnosis to
prophylaxis, empiric and pre-emptive strategies to treatment.
So far, the scientiﬁc community has not achieved to accurately
predict invasive candidiasis and thus to deﬁne populations that
beneﬁt from prophylaxis or early treatment [5]. Although it is
well known that treatment is being initiated too late in the
majority of patients, identiﬁcation of the optimal time point to
commence antifungal therapy remains challenging [6,7]. Inter-
twined with this problem is insufﬁcient support of reliable
mycological assays preventing timely and diagnosis-driven early
treatment initiation [173].
With the diversity of various groups of patients with
organ involvement beyond the bloodstream, a body of
diverse evidence on the best treatments and infectious dis-
eases management decisions, for example, treatment dura-
tion is provided.
In the light of the medical need to analyse the scientiﬁc
evidence in the ﬁeld of invasive Candida diseases, the ESC-
MID European Fungal Infection Study Group (EFISG) devel-
oped comprehensive practical guidance for microbiologists
and clinicians to facilitate evidence-based decision making.
This guideline follows the clinical events in a chronological
order. Prophylaxis in patient populations at risk for invasive
Candida disease is followed by fever- and diagnosis-driven
approaches to early therapy and ﬁnally targeted therapy.
Important clinical questions on catheter management to
step-down strategies are being addressed. Speciﬁc situations
in deep tissue candidiasis are cherished, and for each topic, a
table lists the medical/scientiﬁc evidence.
Methods
An expert group (OAC, MB, TC, JG, BJK, OL and WM) was
set up by EFISG and searched the literature. Documents and
views were shared by email, teleconferences, and face-to-face
meetings during 2010–2012. Once a ﬁrst consensus was
reached, the preliminary recommendations were presented
to the whole group, that is, the other authors, discussed,
developed further, and ﬁnalized as a group consensus. The
methods to evaluate the quality of evidence and to reach
group consensus recommendations are described in this issue
of Clinical Microbiology and Infection [172]. Deﬁnition of the
strength of recommendation is given in Table 1. The quality
of the published evidence is deﬁned in Table 2. Grouping
quality of evidence into three levels only may lead to diverse
types of published evidence being assigned speciﬁcally a level
II. To increase transparency in the evaluation of the evidence,
we added an index (Table 2) to the level II recommendations,
where appropriate. Of note, the strength of recommendation
and the quality of evidence were assigned in two separate
evaluations, thus allowing, for example, a recommendation
strongly supporting a procedure even if there is a lower level
of evidence.
Results
Prophylaxis
Antifungal prophylaxis has been discussed as a promising
approach in ICU patients. At this moment, the optimal target
population for antifungal prophylaxis remains unknown, as
this question has not been sufﬁciently addressed in clinical
trials. Some special populations though have been enrolled in
randomized clinical trials, and recommendations for these
can be given.
TABLE 1. Deﬁnition of the strength of recommendation
Grade ESCMID EFISG
A Strongly supports a recommendation for use
B Moderately supports a recommendation for use
C Marginally supports a recommendation for use
D Supports a recommendation against use
TABLE 2. Deﬁnition of the quality of evidence
ESCMID EFISG
Level
I Evidence from at least one properly designed randomized, controlled trial
II Evidence from at least one well-designed clinical trial, without
randomization, from cohort or case-controlled analytical studies
(preferably from >1 centre); from multiple time series or from dramatic
results of uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive case studies or reports of expert committees
Index (for quality of evidence II)
r Meta-analysis or systematic review of randomized controlled trials
t Transferred evidence, that is, results from different patients’ cohorts, or
similar immune-status situation
h Comparator group is a historical control
u Uncontrolled trial
a Published abstract (presented at an international symposium or meeting)
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Evidence. Patients who had undergone abdominal surgery
recently and who had recurrent gastrointestinal perforations
or anastomotic leakages were treated either with ﬂuconaz-
ole 400 mg/day or with placebo in order to prevent intraab-
dominal Candida infection. The rate of intraabdominal
candidiasis was signiﬁcantly lower in the ﬂuconazole prophy-
laxis group. This clinical trial exhibited high technical quality,
but was performed in a very high baseline incidence popula-
tion and is limited by enrolling 43 evaluable patients only
[8]. In a small non-comparative trial, standard dosed caspo-
fungin was evaluated in the same indication, but no evidence
can be derived [9]. In a large prophylaxis trial, critically ill
surgical patients with an expected ICU stay of ‡3 days were
randomized to receive either ﬂuconazole 400 mg/day or pla-
cebo. The primary endpoint was the time to fungal infection,
which was signiﬁcantly delayed in the ﬂuconazole prophylaxis
group. The trial was well designed and enrolled 260 patients.
A limitation of the study is the inclusion of presumed inva-
sive fungal infection, deﬁned for example, by repeatedly
positive urine cultures and catheter tips with ‡15 yeast col-
onies, into the primary endpoint [10]. In another study,
patients ventilated for 48 h and expected to remain venti-
lated for another ‡72 h received selective digestive decon-
tamination with polymyxin B, neomycin and vancomycin and
were randomized to receive ﬂuconazole 100 mg/day or pla-
cebo. This trial was well designed, and 204 patients were
randomized. Candidaemia was more successfully prevented
in ﬂuconazole recipients, but the selective digestive decon-
tamination regimen used in this clinical trial is not a standard
in most countries [11–13]. Meta-analyses of the clinical trials
above and some other studies on highly selected populations
found ﬂuconazole 400 mg/day to be superior to placebo in
preventing invasive fungal infection in critically ill surgical
patients [14–18]. A more recent clinical trial compared ca-
spofungin 50 mg/day with placebo for prophylaxis in a highly
selected population of ventilated patients receiving antibiot-
ics, having a central venous catheter and fulﬁlling at least
one of the following criteria: parenteral nutrition, dialysis,
major surgery, pancreatitis, systemic steroids or other
immunosuppressant medication. The primary endpoint of
this trial was the incidence of proven and probable invasive
candidiasis according to EORTC/MSG deﬁnitions [19]. The
investigators found a trend only towards a reduced inci-
dence of invasive candidiasis [5]. Other antifungals have been
evaluated in prophylactic indications [20–22]. For ketoconaz-
ole 200 mg/day, evidence of prophylactic beneﬁt is weak
while adverse events and drug interactions limit its use in
general [22]. The same is true for itraconazole 400 mg/day
[21]. Nystatin 4 Mio IU/day has been evaluated, but concept
and patient setting are basically outdated [20]. Intravenous
amphotericin B and the echinocandins have not been sufﬁ-
ciently evaluated in this indication [23]. Antifungal prophy-
laxis in solid organ transplant recipients is not part of this
guideline.
Of note, none of the trials proved a reduction in overall
or attributable mortality. All trials were lacking power to
address the potential emergence of less azole-susceptible
strains during prophylaxis. Apart from historical control
studies in intensive care and abdominal surgical populations,
this has been shown in prophylactic settings in haematology
during substantially longer azole exposure periods [24–26].
Selection of less-susceptible strains remains a caveat against
broadly using antifungals in populations where substantial
beneﬁt has not been proven.
Recommendations. Fluconazole prophylaxis against invasive
candidiasis is recommended in patients who recently under-
went abdominal surgery and had recurrent gastrointestinal
perforations or anastomotic leakages. For further recom-
mendations, refer to Table 3.
Fever-driven approach (empiric)
We deﬁned empiric therapy as a fever-driven approach in
the clinical situation of a patient at risk for invasive candidia-
sis who is persistently febrile with no microbiological evi-
dence of infection.
Evidence. The value of initiating antifungal therapy in this situa-
tion has been addressed in a number of retrospective studies.
Incubation time [27] and time from ﬁrst positive blood culture
drawn to initiation of empiric antifungal therapy correlated
with mortality increases [6,28]. Similarly, in a population-
based retrospective study, empiric antifungal treatment was
associated with higher survival rates, if the isolate turned out
to be susceptible to the empiric regimen [29]. Another retro-
spective study in patients with septic shock due to any cause
found empiric antifungal therapy was given infrequently, and
those with invasive fungal infection not receiving empiric anti-
fungals had a statistically signiﬁcantly higher mortality [7].
Although uncontrolled, all of these studies suggest that ini-
tiating empiric therapy may be beneﬁcial to reduce overall
mortality, but none could identify reliable triggers for
antifungal treatment. They analysed patients with candidaemia
but not the whole population of febrile patients.
One randomized double-blind placebo-controlled clinical
trial evaluated ﬂuconazole 800 mg/day in 270 adult ICU
patients with an APACHE II score >16. Rates of invasive can-
didiasis were not statistically different between the two
groups. The primary endpoint was driven by resolution of
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fever, and empirical ﬂuconazole treatment did not improve
outcome when compared with placebo [30].
Recommendations. Early treatment of presumed fungaemia is
presumably associated with higher survival rates, but the
optimal time point for initiating empiric antifungal treatment
remains undetermined. Due to lack of data, no recommenda-
tion can be given for choosing a speciﬁc drug for fever-dri-
ven therapy. In general, such choice should be based on local
epidemiology and drug–drug interactions in the individual
patient and should be made among the same drugs as rec-
ommended for candidaemia. Further recommendations are
given in Table 4.
Diagnosis-driven approach (pre-emptive)
We deﬁned pre-emptive therapy as therapy triggered by
microbiological evidence of candidiasis without proof of inva-
sive fungal infection.
Evidence. Several studies have addressed diagnosis-driven ther-
apy on grounds of detecting (1,3)-b-D-glucan in serum or
plasma. In a study on 46 ICU patients without infection or with
conﬁrmed bacterial or fungal infection, glucan test results (G-
test; Associates of Cape Cod, East Falmouth, MA, USA) corre-
lated with infection, but not with fungal infection. The authors
suggested using the test to rule out invasive fungal infection
[31]. This was the key ﬁnding in a study using the FungitellTM
TABLE 3. Recommendations on antifungal prophylaxis in ICU patients
Population Intention Intervention SoR QoE References Comment
Recent abdominal surgery AND recurrent
gastrointestinal perforations or
anastomotic leakages
To prevent intraabdominal Candida infection Fluconazole 400 mg/day B I [8] Placebo
N = 43
Caspofungin 70/50 mg/day C IIu [9] Single arm
N = 19
Critically ill surgical patients with an
expected length of ICU stay ‡3 day
To delay the time to fungal infection Fluconazole 400 mg/day C I [10] Placebo
N = 260
Ventilated for 48 h and expected to be
ventilated for another ‡72 h
To prevent invasive candidiasis/candidaemia Fluconazole 100 mg/day C I [162] Placebo
N = 204
SDD used
Ventilated, hospitalized for ‡3 day, received
antibiotics, CVC, and ‡1 of: parenteral
nutrition, dialysis, major surgery,
pancreatitis, systemic steroids,
immunosuppression
To prevent invasive candidiasis/candidaemia Caspofungin 50 mg/day C IIa [5] Placebo
N = 186
EORTC/MSG
criteria used
Surgical ICU patients To prevent invasive candidiasis/candidaemia Ketoconazole 200 mg/day D I [22] Placebo
N = 57
Critically ill patients with risk factors for
invasive candidiasis/candidaemia
To prevent invasive candidiasis/candidaemia Itraconazole 400 mg/day D I [21] Open
N = 147
Surgical ICU with catabolism To prevent invasive candidiasis/candidaemia Nystatin
4 Mio IU/day
D I [20] Placebo
N = 46
SoR, Strength of recommendation; QoE, Quality of evidence; ICU, intensive care unit; CVC, central venous catheter; IU, international units.
The table displays the published evidence; therefore, other available antifungal agents are not mentioned here.
TABLE 4. Recommendations on fever-driven and diagnosis-driven therapy of candidaemia and invasive candidiasis
Population Intention Intervention SoR QoE References
Adult ICU patients with fever despite
broad-spectrum antibiotics and APACHE
II >16
To resolve fever Fluconazole 800 mg/day D I [30]
ICU patients persistently febrile, but without
microbiological evidence
To reduce overall mortality Fluconazole or echinocandin C IIu [28]
[163]
[164]
[7]
[27]
ICU patients with candida isolated from
respiratory secretions
To cure invasive candidiasis or candidaemia early Any antifungal D IIu [42]
ICU patients with positive (1,3)-b-D-glucan
testa
To cure invasive candidiasis or candidaemia early Any antifungal C IIu [39]
[31]
[37]
[35]
[32]
[36]
[34]
[33]
Any patient with Candida isolated from
a blood culture
To cure invasive candidiasis Antifungal treatment A II [46]
[47]
[48]
[49]
APACHE, acute physiology and chronic health evaluation.
aThe (1,3)-b-D-glucan tests have low speciﬁcity and sensitivity with false-positive results in the presence of haemodialysis, other fungal or bacterial infection, wound gauze,
albumin or immunoglobulin infusion.
22 Clinical Microbiology and Infection, Volume 18 Supplement 7, December 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 7), 19–37
(Assoc. of Cape Cod) test, too [32]. Another group of investi-
gators found glucan (FungitecTM; Seigakaku Kogyo, Tokyo,
Japan) testing useful in predicting invasive fungal infection, but in
a very small population of 32 patients only [33]. During twice
weekly monitoring in long-term ICU patients, glucan concen-
trations (GlucatellTM; Cape Cod) were higher in individuals
with proven fungal infection than in those without. As patients
with invasive fungal infection had more bacterial infections and
other intercurrent complications, the test result could still not
clearly distinguish between both groups [34]. Similar results
were found in a surgical ICU patient group (N = 57) and in a
mixed ICU population (N = 95) where higher glucan concen-
trations (FungitellTM) were found in those with invasive candidi-
asis, but still the positive predictive value was limited [35,36].
Findings from a retrospective study on a larger number of
patients (N = 871) were in favour of the test (FungitellTM), but
documented generally higher glucan concentrations in patients
on haemodialysis and in those receiving albumin or intravenous
immunoglobulin infusions [37]. Other reasons for positive test
results in the absence of invasive candidiasis have been
described due to (1,3)-b-D-glucan-containing cell walls of a vari-
ety of fungi, for example, Aspergillus or Histoplasma [32,38].
Indeed, the Fungitell assay has been suggested useful in the
diagnosis of pneumocystis pneumonia as well [39]. A discussion
of glucan tests and their cut-offs to positivity can be found in
the ESCMID Candida Guidelines on Diagnostic Procedures in
this issue [173]. In some of the studies above, it has been stated
that a negative glucan test practically rules out invasive candidi-
asis. Currently, the glucan tests cannot reliably conﬁrm invasive
candidiasis, although there may be a role as part of a set of
diagnostic tools and patient characteristics.
Recommendations on mannan and anti-mannan antibody
detection is part of the EFISG guideline on diagnosis of inva-
sive candidiasis [173].
A controversial issue is the initiation of antifungal therapy
upon Candida isolation from respiratory secretions. Two forms
of pulmonary candidiasis have been distinguished, that is, pul-
monary abscesses resulting from haematogenous spread during
candidaemia, especially in febrile neutropenic patients, and
direct invasion of bronchial and lung tissues. Most articles on
the topic of pulmonary candidiasis were published in the 1970s
and 1990s. There are hardly any data on ICU populations, but
case series of patients with haematological malignancy and stem
cell recipients [40,41]. While Candida can frequently be isolated
from respiratory secretions, it appears that Candida invading
the lung tissue is a very rare event. In a recent prospective
autopsy study (N = 232) on ICU patients, a total of 58% had
proven pneumonia. Regardless of whether Candida had been
isolated pre-mortem or not, in neither case histopathological
proof of Candida tissue invasion was found [42].
Recommendations. Candida isolation from respiratory
secretions should never trigger treatment, but rather be
interpreted as one site of colonization among others. (1,3)-
b-D-glucan detection in serum or plasma prompting antifungal
treatment is marginally supported. Detailed recommenda-
tions are given in Table 4.
Targeted treatment
Candida isolated from a single peripheral blood culture or a
single central-line blood culture deﬁnes candidaemia
[19,43,44]. Previous deﬁnitions may have described asymp-
tomatic patients with a blood culture positive for Candida,
and it has been debated whether there are patients who do
not need antifungal treatment despite a positive blood cul-
ture [45]. This appears to be a very rare clinical situation, as
usually blood cultures are triggered by a clinical sign, for
example, fever. Each case of candidaemia, even from surveil-
lance blood cultures in asymptomatic patients requires tar-
geted treatment [46–49].
Evidence. A plenitude of well-designed clinical trials evaluated
antifungals for the initial treatment of candidaemia and inva-
sive candidiasis. Amphotericin B deoxycholate clearly is a
very potent drug against Candida, but the well-documented
signiﬁcant toxicity justiﬁes a recommendation against using
this compound [50–55]. In the past, several approaches
aimed at reducing toxicity, for example, continuous intrave-
nous administration, but efﬁcacy of this strategy in candidiasis
remains unclear [56]. Amphotericin B lipid complex has been
evaluated in candidaemia, but the single randomized trial to
date has been published as abstract only. Amphotericin B
lipid complex appeared to be less nephrotoxic than the de-
oxycholate formulation although not more effective [57],
ﬁndings which were supported by a phase IV study [58]. As
opposed to laboratory-conﬁrmed adverse events, clinically
deﬁned side effects, such as infusion-related fever and chills,
tend to be underestimated in uncontrolled post-marketing
studies. When ABLC was compared to liposomal amphoteri-
cin B in persistently febrile neutropenic patients, infusion-
related adverse events occurred very frequently [59]. Data
on amphotericin B colloidal dispersion stem from a non-ran-
domized, non-comparative study describing nephrotoxicity in
the same range as found with amphotericin B lipid complex
[60]. Liposomal amphotericin B and amphotericin B deoxych-
olate have not been compared directly in patients with candi-
daemia. But, liposomal amphotericin B appears at least as
effective, but less toxic than the deoxycholate formulation
when considering results from a large clinical trial on candi-
daemia and invasive candidiasis evaluating liposomal ampho-
tericin B and micafungin [61]. Compared to micafungin,
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efﬁcacy was similar, but renal toxicity was higher with liposo-
mal amphotericin B [61,62]. Caspofungin when compared to
amphotericin B deoxycholate was as effective, but signiﬁ-
cantly less toxic [55]. A clinical strategy became feasible,
which avoided amphotericin B toxicity without losing efﬁ-
cacy. Two doses of micafungin (100, 150 mg/day) were com-
pared with caspofungin in a phase III trial. All three regimens
were similarly effective and safe [63]. While all echinocandin
trials above proved statistical non-inferiority of the experi-
mental study drug as compared to standard regimens, anidu-
lafungin was found to be superior over ﬂuconazole [64]. In
particular, the outcomes for patients with Candida albicans
were signiﬁcantly better with anidulafungin (81%) than with
ﬂuconazole (62%). The latter result remained valid in a sub-
sequent subgroup analysis of ICU patients: global response
for anidulafungin 67% vs. ﬂuconazole 47% [65].
With regard to Candida, all three echinocandins exhibit a
broad spectrum activity; acquired resistance is rare, although
there has been a ﬁrst large epidemiological evaluation
describing acquisition of resistance genes in Candida glabrata
[66]. There is an ongoing debate on whether echinocandins
are appropriate for treating Candida parapsilosis, because min-
imal inhibitory concentrations are found to be higher than
those of other Candida species. Overall, that is, clinical and
microbiological, response rates in C. parapsilosis infection
were not statistically signiﬁcantly different throughout the
echinocandin trials: for caspofungin/amphotericin B, the suc-
cess rates were 70% and 65%, for micafungin/liposomal
amphotericin B 89.2% and 86.7%, for caspofungin/micafungin
100/150 rates were 64.3%, 75.9% and 71.4%, and for anidula-
fungin/ﬂuconazole, they were 64% and 83% [55,61,63]. How-
ever, there were numerically higher numbers of persistent
fungaemia due to C. parapsilosis during caspofungin as com-
pared to amphotericin B deoxycholate treatment [55], and
during standard dose caspofungin as compared to high dose,
that is, 150 mg/day, caspofungin [67], and the eradication
rate in C. parapsilosis fungaemia was lower with anidulafungin
than with ﬂuconazole [64]. It is important to note that none
of these trials were powered to detect such differences.
Two further aspects we considered important when
interpreting the latter trial are (i) the microbiological eradi-
cation rate as well as the overall success rate in C. albicans
infection was higher with anidulafungin than with ﬂuconaz-
ole and (ii) Candida krusei infection was excluded from the
anidulafungin trial, because of ﬂuconazole being the compar-
ator drug [64].
In the clinical trials, all three echinocandins were well tol-
erated and appeared very safe. Micafungin though carries a
warning label against use unless other antifungals are not
appropriate by the European Medicines Agency, which
reﬂects results of rats developing liver tumours after very
long and high-dosed exposure [68]. This statement has elic-
ited some debate in terms of its relevance to humans, but
has not been withdrawn or disproved so far.
An advantage of the echinocandin class is the low poten-
tial for drug–drug interactions. For anidulafungin, no interac-
tions have been described, and for micafungin, very few
relevant interactions need to be considered [68,69]. Co-
administering caspofungin with rifampin lowers caspofungin
exposure, and it has been recommended to increase the
dose of caspofungin in the rare cases, where both drugs
need to be administered concomitantly. In addition, caspo-
fungin dose has to be increased in patients with a high body
weight [70].
For many years, ﬂuconazole was considered the drug of
choice for candidaemia [71–73]. This was based on a great
number of clinical trials evaluating ﬂuconazole in this indication
[52–54,64,74–76]. As anidulafungin was superior over ﬂuco-
nazole in patients with candidaemia, especially those infected
with C. albicans, we do no longer consider ﬂuconazole as the
drug of choice [64]. Fluconazole was inferior in the subgroup
of patients with high APACHE scores and is known to have a
limited spectrum of activity, being inactive against C. krusei and
being considered hardly active in C. glabrata infection. Microbi-
ologically, it might though be the better drug against C. par-
apsilosis, which is supported by a trend towards better
outcomes in the comparative trial [64], but clinical proof is
not in support of this. There have been no trials with sufﬁ-
cient power to assess non-inferiority of echinocandins for
C. parapsilosis. In a large clinical trial, voriconazole was non-
inferior to amphotericin B deoxycholate followed by ﬂuconaz-
ole [43], and voriconazole offers an important additional treat-
ment option for ﬁrst-line and salvage situations [77,78]. Still
there are certain limitations, that is, the multiple drug–drug
interactions [79], the limit of the intravenous use to 14 days
duration [79] and the variable pharmacokinetics of the drug
[80]. Itraconazole yielded negative results when compared to
ﬂuconazole [76]. There are no published data on posaconaz-
ole treatment of candidaemia.
Very few clinical trials used combination treatment. Lipid-
based amphotericin B was supplemented with placebo or
efungumab, a monoclonal antibody targeting heat shock pro-
tein 90 (HSP-90), in 139 patients. The study design and anal-
ysis drew substantial criticism for (i) enrolling an ill-deﬁned
patient population, for example, symptomatic candiduria, (ii)
enrolling patients with negative fungal cultures and (iii)
excluding patients from the efﬁcacy population who died
while on treatment [81]. Furthermore, the trial allowed
extensive prior antifungal treatment, used a short, 10-day,
treatment time until response evaluation and did not specify
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the proportion of patients receiving which type of lipid-based
amphotericin B formulation.
The combination of amphotericin B deoxycholate and
ﬂuconazole has been as effective as ﬂuconazole monotherapy
in a randomized trial, but patients had an increased risk of
toxicity and no survival beneﬁt [74]. A small study (N = 72)
comparing ﬂuconazole with amphotericin B deoxycholate
and 5-ﬂucytosine showed no difference in overall response
to treatment [75].
Recommendations. Targeted treatment of candidaemia with
echinocandins is strongly recommended. The recommenda-
tion for liposomal amphotericin B or voriconazole is less
stringent, and ﬂuconazole is recommended with marginal
strength only, except for C. parapsilosis. For detailed recom-
mendations, refer to Table 5.
Duration of targeted treatment, step-down to oral treat-
ment and diagnostics in candidaemia
Evidence. The duration of treatment depends on the extent
of organ involvement. In a population without documented
organ involvement, treatment aims to clear the infection
and at the same time to avoid deep-organ involvement. This
can be achieved by treating for 14 days after the end of
candidaemia [82]. To determine the end of candidaemia, at
least one blood culture per day should be taken until cul-
ture results come back negative. Treatment can probably
be simpliﬁed by stepping down to oral ﬂuconazole after
10 days of intravenous treatment, if the patient is stable,
tolerates the oral route and if the species is susceptible
[55,63,64].
The diagnostic procedures to detect organ involvement
comprise transoesophageal echocardiography, fundoscopy
and search for a thrombus. A recent observational study
found infectious endocarditis in 8.3% of patients with candi-
daemia; the majority of these patients had no well-estab-
lished risk factors, that is, vascular prosthesis or persistent
candidaemia [83].
Some prospective studies addressed ocular candidiasis as
complication of candidaemia. The diagnostic approach was
usually based on weekly eye examinations. Immunosuppres-
sion and repeatedly positive blood cultures are risk factors
TABLE 5. Recommendations on initial targeted treatment of candidaemia and invasive candidiasis in adult patients
Intervention SoR QoE References Comment
Anidulafungin 200/100 mg A I [64] Consider local epidemiology (Candida parapsilosis, Candida krusei), less
drug–drug interactions than caspofungin
Caspofungin 70/50 mg A I [67]
[55]
[63]
Consider local epidemiology (C. parapsilosis)
Micafungin 100 mg A I [61]
[63]
Consider local epidemiology (C. parapsilosis), less drug–drug interactions
than caspofungin, consider EMA warning label
Amphotericin B liposomal 3 mg/kg B I [61]
[62]
Similar efﬁcacy as micafungin, higher renal toxicity than micafungin
Voriconazole 6/3 mg/kg/daya,b B I [43]
[78]
[77]
Limited spectrum compared to echinocandins, drug–drug interactions,
limitation of IV formulation in renal impairment, consider therapeutic drug
monitoring
Fluconazole 400–800 mga C I [165]
[53]
[74]
[54]
[64]
[76]
[75]
[73]
[72]
Limited spectrum, inferiority to anidulafungin (especially in the subgroup
with high APACHE scores), may be better than echinocandins against
C. parapsilosis
Amphotericin B lipid complex 5 mg/kg C IIa [57]
[58]
Amphotericin B deoxycholate 0.7–1.0 mg/kg D I [50]
[51]
[165]
[53]
[54]
[55]
Substantial renal and infusion-related toxicity
Amphotericin B deoxycholate plus ﬂuconazole D I [74] Efﬁcacious, but increased risk of toxicity in ICU patients
No survival beneﬁt
Amphotericin B deoxycholate plus 5-ﬂuorocytosine D II [75]
Efungumab plus lipid-associated amphotericin B D II [166]
Amphotericin B colloidal dispersion D IIa [60]
Itraconazole D IIa [76]
Posaconazole D III No reference found
EMA, European Medicines Agency.
Comparative clinical trials did not prove a survival beneﬁt of one treatment over another. Primary intention of treating candidaemia is clearing the blood stream.
aNot all experts agreed, SoR results from a majority vote.
bThe licensed maintenance dosing is 4 mg/kg/day.
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for eye involvement and should prompt fundoscopic evalua-
tion [84,85]. Other risk factors coincided with those for can-
didaemia [86]. In a large clinical trial, fundoscopy revealed
ocular candidiasis in 16% of patients with candidaemia, the
majority had eye involvement upon diagnosis of candidaemia
and additional cases were detected during treatment. Most
of the patients had chorioretinitis while endophthalmitis was
uncommon (1.6%) [43,87].
In patients with a central venous catheter or a peripherally
inserted central catheter, the possibility of a thrombus
should be taken into account.
Recommendations. For uncomplicated candidaemia, treat-
ment duration of 14 days after the end of candidaemia is
recommended. The end of candidaemia should be deter-
mined by at least one blood culture per day until nega-
tivity. Transoesophageal echocardiography and fundoscopy
should be performed to detect organ involvement.
Switching to oral treatment can be considered after
10 days of intravenous therapy. For detailed recommenda-
tions, refer to Table 6.
Catheter-related blood stream infection
In general, indwelling lines need to be removed early after
diagnosing catheter-related candidaemia; however, removal
or exchange is not always possible. As the predominant
mode of device-related infections is likely bioﬁlm formation
[88], certain differences in antifungal activity on Candida
grown in bioﬁlms vs. planktonic cells may help decision mak-
ing. Liposomal amphotericin B, amphotericin B lipid complex,
caspofungin and micafungin were active against Candida cells
in bioﬁlms, while cells were resistant towards amphotericin
B deoxycholate, ﬂuconazole, ravuconazole and voriconazole
[89]. In animal models, amphotericin B lipid complex and ani-
dulafungin reduced candida cell numbers in bioﬁlms, while
ﬂuconazole did not [90,91].
Evidence. Duration of candidaemia: In a prospective random-
ized clinical trial comparing ﬂuconazole with amphotericin B
deoxycholate for candidaemia in non-neutropenic patients
[53], the exchange of catheters – not over a guidewire –
within the ﬁrst 24 h was associated with a shorter duration
of candidaemia [92]. A post hoc analysis of two pooled phase
III trials comparing micafungin to caspofungin or liposomal
amphotericin B (N = 842) did not ﬁnd an improved time to
mycological eradication, if central venous catheters were
removed within 24 or 48 h [61,63,93].
Impact of catheter removal on mortality: Catheter removal
was identiﬁed as a protective factor in a prospective study
on 272 episodes of candidaemia [94]. A population-based
study analysing 345 cases of candidaemia concluded that
catheter removal was associated with an improved probabil-
ity of survival [95,96]. In a retrospective analysis on 92
patients with cancer, removal of non-tunnelled central
venous catheters ‡72 h after diagnosis of candidaemia was
associated with a signiﬁcantly decreased survival rate, [97]
and in a univariate analysis on 244 ICU patients with candida-
emia, catheter removal within 24 h was associated with bet-
ter survival [73]. Early removal of central venous catheters,
that is, within 24 or 48 h, had no impact on survival at 28 or
42 days in the post hoc analysis of the two pooled micafungin
phase III trials [93]. However, in a recent individual patient
level (n = 1915) pooled analysis of seven prospective ran-
domized controlled trials for treatment of invasive candidiasis
and candidaemia, the removal of a central venous catheter
was associated with decreased mortality (OR, 0.50; 95% CI,
0.35–0.72, p = 0.0001) [98].
Recommendations. In candidaemia, removal of indwelling intra-
vascular catheters is strongly recommended. When catheter
removal is not possible, lipid-based amphotericin B formula-
tion or an echinocandin is preferable. For detailed recom-
mendations, refer to Table 7.
TABLE 6. Recommendations on the duration of targeted treatment, step-down to oral treatment and diagnostics in
candidaemia
Population Intention Intervention SoR QoE References
Candidaemia with no
organ involvement
detected
To avoid organ
involvement
Treat for 14 days after the end of candidaemia B II [82]
Take at least one blood culture per day until negative B III No reference found
To detect organ
involvement
Transoesophageal echocardiography B IIa [83]
Fundoscopy B II [87]
[84]
[85]
[86]
If CVC, PICC or intravascular devices, search for
thrombus
B III No reference found
Any To simplify treatment *Step-down to ﬂuconazole after 10 days of IV, if species
is susceptible, patient tolerates PO, and patient is stable
B II [64]
[55]
[63]
CVC, central venous catheter; PICC, peripherally inserted central catheter.
*If C. parapsilosis is identiﬁed, step-down to ﬂuconazole may occur earlier.
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Urinary tract infection
Candiduria is commonly encountered in hospitalized patients,
particularly those with a urinary catheter. Candiduria is indic-
ative for a wide spectrum of conditions which may or may
not require treatment.
Evidence. Asymptomatic candiduria has been followed long
term, but no adverse consequences have been described [99].
Funguria resolved without speciﬁc treatment in 76% of a large
(N = 861) clinical cohort [100]. In a well-designed trial, ﬂuco-
nazole was superior over placebo in clearing candiduria, but at
2-week follow-up candiduria rates were similar between both
groups. Removal of the urinary catheter was the most promis-
ing intervention [101]. Bladder irrigation appeared as a rarely
used alternative, if treatment is judged necessary [100,102]. In
symptomatic candida cystitis, ﬂuconazole has been advocated
as well as amphotericin B deoxycholate with or without 5-ﬂu-
cytosine, but clinical data are sparse for all these approaches
[100,103]. In the rare cases of fungus balls, surgical interven-
tion is the only promising treatment option [104,105]. Echino-
candins do not achieve high urine concentrations and are thus
rarely considered in urinary tract infection. Some cases though
have successfully been treated with caspofungin. These were
partly candidaemias with concomitant candiduria and partly
infections limited to the urinary tract [106]. For candida
pyelonephritis, ﬂuconazole and amphotericin B deoxycholate
each with or without ﬂucytosine may be used, but clinical tri-
als have not been performed.
Recommendations. Asymptomatic candiduria should not be
treated, while symptomatic cystitis should be treated with
ﬂuconazole, if the isolate is susceptible. Fungus balls or casts
in the pyelum or urinary bladder need surgical intervention.
To cure pyelonephritis ﬂuconazole as well as lipid-based
amphotericin B are recommended either alone or in combi-
nation with ﬂucytosine. For detailed recommendations, refer
to Table 8.
Ocular candidiasis
Ocular candidiasis may cause pain or disturbed vision, but
should rather be diagnosed prior to becoming clinically
symptomatic [86,107]. There are two forms of ocular candi-
diasis. Chorioretinitis is the inﬂammation of the choroid and
the retina, while endophthalmitis is the inﬂammation of the
vitreous body. Fungal endophthalmitis may develop from
chorioretinitis as advanced disease and is associated with
poor visual outcomes [108]. Most publications in this ﬁeld
report on individual cases or small series, and not all clearly
differentiate between the two forms of ocular involvement.
Evidence. Amphotericin B deoxycholate has been advocated
for ocular candidiasis, but dosing information was not always
disclosed in the early reports [107,109,110]. Amphotericin B
deoxycholate followed by ﬂuconazole has been used success-
fully to treat ocular involvement in the voriconazole phase III
trial [43,87]. Information on amphotericin B lipid complex
use in ocular candidiasis is sparse. One case of breakthrough
ocular candidiasis during amphotericin B lipid complex treat-
ment has been described [111], and another case in which
amphotericin B lipid complex was successfully used with con-
comitant ﬂucytosine [112]. In a rabbit model evaluating the
penetration of amphotericin B deoxycholate, liposomal
amphotericin B and amphotericin B lipid complex, the high-
est penetration into the eye was achieved with the liposomal
formulation [113,114]. Intravitreal injection of amphotericin
B deoxycholate 5–10 lg dissolved in 0.1 mL sterile water is
part of standard approaches and frequently combined with
systemic antifungals and surgery [110,115].
All three echinocandins appear to have limited penetration
into the eye [116–118]. With caspofungin treatment, varying
outcomes have been reported, some patients failed treat-
ment [116,119], while only two patients have been described
who responded successfully [120,121].
Successful use of ﬂuconazole has been reported in case ser-
ies, where it was used at doses varying from 100 to 400 mg
TABLE 7. Recommendations on catheter management in candidaemia
Population Intervention SoR QoE References
Central venous catheter can be removed Remove indwelling lines (not over a guidewire) A IIr [98]
Central venous catheter cannot be removed Echinocandin, liposomal amphotericin B or amphotericin
B lipid complex
B IIr [98]
[90]
[89]
[91]
[93]
[92]
Azole or amphotericin B deoxycholate D IIr [95]
[98]
[73]
[97]
[96]
[94]
Interventions are intended to clear candidaemia and to improve survival.
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for at least two and up to 8 weeks. A number of these patients
were treated with concomitant systemic amphotericin B de-
oxycholate [122–125]. Overall ﬂuconazole 400 mg alone
appeared to be effective in less-advanced disease [126].
In advanced disease, a combined strategy of surgical inter-
vention with intraocular amphotericin B deoxycholate, and
systemic ﬂuconazole has successfully been applied [110]. Sys-
temic antifungal treatment duration varied between 2 and
12 weeks [110,127]; an individual decision will usually take
reduction of immunosuppression and the extent of ocular
candidiasis into consideration.
More recently, intravitreal voriconazole has been evalu-
ated, and in animal models, doses of 25 mg/L vitreous, that
is, 100 lg absolute in an adult human eye, were found to be
safe [126,128]. Published cases were frequently treated with
combined approaches, so that the efﬁcacy of voriconazole
monotherapy has not yet been deﬁned [126,129,130]. In the
post hoc analysis of eye involvement in the voriconazole
phase III trial on candidaemia, treatment was successful in
most cases, but endophthalmitis was rare [87].
Recommendations. In ocular candidiasis, liposomal amphoteri-
cin B either alone or combined with ﬂucytosine is recom-
mended when the susceptibility of the isolate is unknown.
In susceptible isolates ﬂuconazole or voriconazole are the
drugs of choice. In the case of vitreal involvement, vitrec-
tomy and intravitreal injection of amphotericin B are rec-
ommended in addition to systemic therapy. For details,
refer to Table 9.
Candida meningitis
Candida meningitis is a rare disease, and only very few
reports have been published. Prognosis is generally poor
[131].
Evidence. Liposomal amphotericin B has been combined with
ﬂucytosine for 10 weeks, followed by ﬂuconazole for
5 weeks in a neonate [132]. In another neonate, a Candida
isolate was resistant to ﬂucytosine, and liposomal amphoteri-
cin B was combined with ﬂuconazole for a total of 4 weeks
[133]. Amphotericin B deoxycholate/ﬂucytosine treatment
had failed in the latter patient [133]. However, it is unclear
to what extent these experiences can be extrapolated
applied to adults. In a series of HIV-infected patients with
candida meningitis, amphotericin B deoxycholate was fre-
quently combined with ﬂucytosine, and four of ﬁve patients
were treated successfully [131]. In two other series, 27 of
34 patients survived after similar treatments [134,135]. In
some cases, individualized maintenance regimens were given
[131,134]. In the more recent case reports, amphotericin B
deoxycholate toxicity frequently forced to replace it with
the liposomal amphotericin B.
Fluconazole has been used in higher doses to treat Can-
dida meningitis, when lower doses proved insufﬁcient [136].
Published data on voriconazole use in Candida meningitis are
sparse. In central nervous system, aspergillosis voriconazole
is the drug of choice [137]. Brain tissue levels of voriconaz-
ole are satisfactory, but concentrations in cerebrospinal ﬂuid
are variable [138].
With caspofungin, a patient was cured from Candida men-
ingitis refractory to amphotericin B deoxycholate and ﬂuco-
nazole [139], but poor penetration of echinocandins limit
their use in central nervous system infection.
Recommendations. Due to lack of data, no strong recommen-
dation can be given. Treatment should build on liposomal
amphotericin B combined with ﬂucytosine or with ﬂuconaz-
ole if isolate is susceptible. For detailed recommendations,
refer to Table 10.
TABLE 8. Recommendations on Candida urinary tract infections
Population Intention Intervention SoR QoE References
Asymptomatic To clear candiduria Nonea A IIu [100]
[99]
Fluconazole 200 mg for 14 daysb C I [100]
[101]
Removal of urinary catheter B I [101]
Amphotericin B deoxycholate bladder irrigation C IIr,u [100]
[102]
Cystitis To cure Fluconazoleb A III [100]
Amphotericin B deoxycholate +/) ﬂucytosine B III
Fungus balls To cure Surgical intervention A III [104]
[105]
Pyelonephritis To cure Caspofungin 70/50 mg for 9–28 days C III [106]
Fluconazole +/) ﬂucytosineb A III No reference found
Lipid-based amphotericin B +/) ﬂucytosine A III No reference found
aIn pre-operative patients, treatment is indicated to suppress candiduria.
bIf species is susceptible.
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Candida endocarditis
Candida endocarditis may manifest as native valve endocardi-
tis, prosthetic valve endocarditis or infection in the presence
of pacemaker or other implanted material prone to bioﬁlm
formation. In general, prognosis is poor with 1-year mortality
>50% and substantial relapse rates [140–142].
Evidence. In native valve Candida endocarditis, primary inten-
tion is to decrease mortality [140]. Retrospective data sug-
gest that patients should undergo surgery within the ﬁrst
week [140,141,143]. Treatment regimens published are lipo-
somal amphotericin B or caspofungin, either one has been
combined with ﬂucytosine [140,141]. In prosthetic valve Can-
dida endocarditis, valve replacement surgery needs be per-
formed as soon as possible [142,143]. In single cases where
comorbidities prevented surgery, caspofungin and liposomal
amphotericin B were used successfully with or without sub-
sequent life-long suppressive therapy with ﬂuconazole
[142,144,145]. In patients with pacemakers, implantable deﬁ-
brillators or assist devices, removal of the device appears
mandatory [146].
Recommendations. In native valve Candida endocarditis, sur-
gery within a week is recommended, and in prosthetic valve
Candida endocarditis, even earlier surgery may be beneﬁcial.
The antifungal regimen of choice is liposomal amphotericin
B, which can be combined with ﬂucytosine. For detailed rec-
ommendations, refer to Table 11.
TABLE 9. Recommendations on Candida chorioretinitis and endophthalmitis
Population Intervention SoR QoE References
Susceptibility of isolate unknown Liposomal amphotericin B 5 mg/kg B III [113]
[114]
[119]
Liposomal amphotericin B plus ﬂucytosine B III No reference found
Amphotericin B lipid complex plus ﬂucytosine B III [112]
Amphotericin B deoxycholate 0.7–1.0 mg/kg (for 3–7 days), followed by
ﬂuconazole 400 mg
C II [87]
Amphotericin B deoxycholate 0.6–1.0 mg/kg C IIr [107]
[109]
[110]
Amphotericin B lipid complex 5 mg/kg C III [111]
Amphotericin B deoxycholate plus ﬂucytosine C III No reference found
Caspofungin 50–100 mg D IIu [116]
[120]
[121]
[119]
[130]
Susceptible isolate Fluconazole 400–800 mg A IIu [122]
[123]
[124]
[126]
[125]
Voriconazole 12/6 mg/kg IV, followed by 400 mg PO A IIu [129]
[87]
[130]
[119]
[126]
[128]
Vitreal involvementa Amphotericin B deoxycholate 5–10 lg intravitreal injection B IIu [110]
[167]
[115]
[168]
Vitrectomy plus intravitreal amphotericin B 5–10 lg, ﬂuconazole
400 mg for ‡2 weeks
B IIu [110]
[127]
[125]
Voriconazole 100 lg intravitreal injection B III [128]
[126]
Frequent eye examinations are needed to detect disease progression.
aEndophthalmitis requires local and systemic treatment plus surgery.
TABLE 10. Recommendations on Candida meningitis
Intervention SoR QoE References
Liposomal amphotericin B 3 mg/kg for
10 weeks + ﬂucytosine 150 mg/kg for
10 weeks, followed by ﬂuconazole 3 mg/kg
for 5 weeks
B III [132]
Liposomal amphotericin B 3 mg/kg for
4 weeks + ﬂuconazole 6 mg/kg for 4 weeks
B III [133]
Voriconazole 12/6 mg/kga C III [137]
[138]
[43]
Fluconazole 800 mg C III [136]
[169]
Amphotericin B deoxycholate 0.5–1.0 mg/kg
for >2 weeks +/) ﬂucytosine 30–120
mg/kg for >2 weeks
D IIu [131]
[134]
[133]
[135]
Caspofungin 70/50 mg for 4 weeks, followed
by ﬂuconazole 400 mg for 2 weeks
D III [139]
[170]
Interventions are intended to cure Candida meningitis.
aTherapeutic drug monitoring recommended.
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Bone and joint candidiasis
Candida infections of bones and joints are grouped into
osteomyelitis/spondylodiscitis, arthritis and prosthetic joint
infection. No randomized clinical trials have been conducted,
so that evidence for the best therapeutic approach is some-
what limited.
Evidence. Typical indications for surgical debridement in oste-
omyelitis or spondylodiscitis are instability or large abscesses.
Usually, cases of Candida osteomyelitis are diagnosed by
biopsy. Over the years, most experience has been gathered
with amphotericin B formulations, sometimes combined with
ﬂucytosine, sometimes followed by ﬂuconazole [147]. Today,
in patients with osteomyelitis as well as spondylodiscitis due
to a susceptible isolate, treatment can commence with
liposomal or lipid complex amphotericin B to be followed by
ﬂuconazole [147], or – if isolate is susceptible – ﬂuconazole
monotherapy may be used from the beginning [147–149].
Posaconazole has been successfully used in a single case as
add-on during unsuccessful caspofungin treatment [150].
Voriconazole treatment has been reported in three
patients with Candida osteomyelitis [78]. In addition, in Asper-
gillus osteomyelitis, voriconazole was used either as the only
antifungal or as maintenance following liposomal amphoteri-
cin B [151]. Use of echinocandins has not been reported,
with the exception of four patients with osteomyelitis
and/or septic arthritis successfully treated with caspofungin
[120].
TABLE 11. Recommendations on Candida endocarditis
Population Intention Intervention SoR QoE References
Native valve To cure Surgery within 1 week A II [140]
[143]
[171]
Liposomal ampho B +/) ﬂucytosine for 6–8 weeks, followed by ﬂuconazole B II [171]
Caspofungin +/) ﬂucytosine C II [171]
Prosthetic valve To cure Surgery within days A III [142]
[143]
Prosthetic valve, if surgery not possible To cure Liposomal amphotericin B 5 mg/kg B III [142]
Caspofungin 70/50 mg B III [142]
To suppress infection Fluconazole 400–800 mg, life long C III [142]
[145]
Pacemaker, ICD, VAD To cure Removal A II [146]
[144]
ICD, implantable cardioverter deﬁbrillator; VAD, ventricular assist device.
Surgery – even if restricted to removal of hardware – always needs to be combined with systemic antifungal treatment.
TABLE 12. Recommendations on bone and joint candidiasis
Population Intention Intervention SoR QoE References
Osteomyelitis/spondylodiscitis To cure Surgical debridementa,b C III [147]
Fluconazole 400 mg for 6–12 monthsc A IIu [149]
[148]
[147]
Liposomal amphotericin B 3 mg/kg or amphotericin B lipid
complex 5 mg/kg for 2–6 weeks followed by ﬂuconazole 400 mg
for 5–11 monthsc
A IIu [149]
[147]
Posaconazole 800 mg for ‡6 weeksc C III [150]
Voriconazole 12/6 mg/kg for 6–12 weeksc B IIt [78]
Caspofungin 100 mg for 3 weeks, followed by ﬂuconazole 400 mg
for ‡4 weeksc
B II [120]
Arthritis To cure Liposomal Ampho B 3 mg/kg/ABLC 5 mg/kg 2 weeks, followed by
ﬂuconazole 400 mg for ‡4 weeksc
A IIu [154]
Fluconazole 400 mg for ‡6 weeksc A IIu [155]
Voriconazole 12/6 mg/kg for ‡6 weeksc B III [156]
Caspofungin 70/50 mg for 6 weeks C II [120]
[152]
[153]
Prosthetic joint infection To cure Prosthesis removalb A III [154]
[158]
[157]
Prosthetic joint infection
with prosthesis retention
To suppress infection Fluconazole 400 mg, life long A III [160]
[161]
[159]
[157]
aIndications for surgery are, for example, instability or large abscess.
bSurgery needs to be combined with antifungal treatment.
cTreat longer if erythrocyte sedimentation rate or C-reactive protein not returned to normal.
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A case of Candida shoulder arthritis was cured with a 3-
week course of caspofungin [152], and a knee arthritis was
treated with 7 weeks of caspofungin added on to a failing
ﬂuconazole therapy [153]. The most prevalent joint prone to
Candida infection is the knee. Standard treatment of knee
arthritis due to Candida was an amphotericin B–based
approach, which may have been supplemented with ﬂucyto-
sine [154]. More recently, ﬂuconazole and voriconazole were
used with success [78,155,156].
Joint prosthesis is an important risk factor for Candida
arthritis, and prosthesis is mandatory [154,157,158]. If the
prosthesis must be retained, life-long suppressive treat-
ment should be tried. In some patients, surgery was con-
sidered not possible, and knee or hip prosthetic joint
arthritis was cured with use of ﬂuconazole alone
[157,159–161]. Bias towards publishing the unusual and
successful cases can be assumed, so that the standard
approach remains prosthesis removal and an intensive
course of systemic antifungals.
Recommendations. Treating osteomyelitis, spondylodiscitis or
arthritis with ﬂuconazole is strongly recommended if species
is susceptible. Fluconazole may be preceded by an induction
phase with lipid-based amphotericin B. If joint prosthesis can-
not be removed, lifelong ﬂuconazole suppressive therapy is
indicated. For details, refer to Table 12.
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